[1] Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13–23. doi:10.1176/appi.ajp.160.1.13.
[2] Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998;28:309–69.
[3] Berridge KC. Reward learning: Reinforcement, incentives, and expectations. Psychol Learn Motiv 2000;40:223–78. doi:10.1016/S0079-7421(00)80022-5.
[4] Heinz A. [Anhedonia--a general nosology surmounting correlate of a dysfunctional dopaminergic reward system?]. Nervenarzt 1999;70:391–8.
[5] Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005;79:59–68. doi:10.1016/j.schres.2005.01.003.
[6] Heinz A, Schlagenhauf F. Dopaminergic Dysfunction in Schizophrenia: Salience Attribution Revisited. Schizophr Bull 2010;36:472–85. doi:10.1093/schbul/sbq031.
[7] Berridge KC. From prediction error to incentive salience: mesolimbic computation of reward motivation. Eur J Neurosci 2012;35:1124–43. doi:10.1111/j.1460-9568.2012.07990.x.
[8] Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry 2008;13:239, 267–76. doi:10.1038/sj.mp.4002058.
[9] Cicero DC, Docherty AR, Becker TM, Martin EA, Kerns JG. Aberrant Salience, Self-Concept Clarity, and Interview-Rated Psychotic-Like Experiences. J Pers Disord 2015;29:79–99. doi:10.1521/pedi_2014_28_150.
[10] Jaspers K. General psychopathology. Johns Hopkins University Press; 1997.
[11] Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007;191:391–431. doi:10.1007/s00213-006-0578-x.
[12] Eckblad M, Chapman LJ. Magical ideation as an indicator of schizotypy. J Consult Clin Psychol 1983;51:215–25. doi:10.1037/0022-006X.51.2.215.
[13] Chapman LJ, Chapman JP, Raulin ML. Body-image aberration in Schizophrenia. J Abnorm Psychol 1978;87:399–407.
[14] Lenzenweger MF, Bennett ME, Lilenfeld LR. The Referential Thinking Scale as a measure of schizotypy: Scale development and initial construct validation. Psychol Assess 1997;9:452–63. doi:10.1037/1040-3590.9.4.452.
[15] Schneider K. Clinical psychopathology. New York: Grune & Stratton; 1959.
[16] Soares-Weiser K, Maayan N, Bergman H, Davenport C, Kirkham AJ, Grabowski S, et al. First rank symptoms for schizophrenia. Cochrane Database Syst Rev 2015;1:CD010653. doi:10.1002/14651858.CD010653.pub2.
[17] American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5. American Psychiatric Association; 2013.
[18] ICD-10 Version:2010 n.d. https://icd.who.int/browse10/2010/en#!Q77 (accessed May 25, 2019).
[19] Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie., Scharfetter C. Das AMP-System : Manual zur Dokumentation psychiatrischer Befunde. Springer-Verlag; 1972.
[20] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–76. doi:10.1093/schbul/13.2.261.
[21] Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.
[22] HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–5.
[23] Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–35.
[24] Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie, Broome MR, Bottlender R, Rösler M, Stieglitz R-D. The AMDP system : manual for assessment and documentation of psychopathology in psychiatry. n.d.
[25] Jensen J, Kapur S. Salience and psychosis: moving from theory to practise. Psychol Med 2009;39:197–8. doi:10.1017/S0033291708003899.
[26] Lelli L, Godini L, Lo Sauro C, Pietrini F, Spadafora M, Talamba GA, et al. Validation of the Italian Version of the Aberrant Salience Inventory (ASI): a New Measure of Psychosis Proneness Validazione della Versione italiana dell’Aberrant Salience Inventory (ASI): una nuova misura per la vulnerabilità alla psicosi. vol. 21. 2015.
[27] Raballo A, Cicero DC, Kerns JG, Sanna S, Pintus M, Agartz I, et al. Tracking salience in young people: A psychometric field test of the Aberrant Salience Inventory (ASI). Early Interv Psychiatry 2019;13:64–72. doi:10.1111/eip.12449.
[28] Reininghaus U, Kempton MJ, Valmaggia L, Craig TKJ, Garety P, Onyejiaka A, et al. Stress Sensitivity, Aberrant Salience, and Threat Anticipation in Early Psychosis: An Experience Sampling Study. Schizophr Bull 2016;42:712–22. doi:10.1093/schbul/sbv190.
[29] Nordgaard J, Arnfred SM, Handest P, Parnas J. The diagnostic status of first-rank symptoms. Schizophr Bull 2008;34:137–54. doi:10.1093/schbul/sbm044.
[30] Howes OD, Kapur S. The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway. Schizophr Bull 2009;35:549–62. doi:10.1093/schbul/sbp006.
[31] Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Valli I, Tabraham P, et al. Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia. vol. 66. 2009.
[32] Maj M. Narrowing the gap between ICD/DSM and RDoC constructs: possible steps and caveats. World Psychiatry 2016;15:193–4. doi:10.1002/wps.20370.
[33] van Os J. “Salience syndrome” replaces “schizophrenia” in DSM-V and ICD-11: psychiatry’s evidence-based entry into the 21st century? Acta Psychiatr Scand 2009;120:363–72. doi:10.1111/j.1600-0447.2009.01456.x.
[34] van Os J. A salience dysregulation syndrome. Br J Psychiatry 2009;194:101–3. doi:10.1192/bjp.bp.108.054254.